IDEXX Laboratories, Inc (IDXX) is a leading diagnostics & research business based in the US. IDEXX Laboratories is listed on the NASDAQ and employs 9,000 staff. All prices are listed in US Dollars.
Since the stock market crash in March caused by coronavirus, IDEXX Laboratories's share price has had significant positive movement.
Its last market close was $363.87, which is 23.57% up on its pre-crash value of $278.11 and 115.75% up on the lowest point reached during the March crash when the shares fell as low as $168.65.
If you had bought $1,000 worth of IDEXX Laboratories shares at the start of February 2020, those shares would have been worth $664.07 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $1,320.85.
|52-week range||$168.65 - $407.86|
|50-day moving average||$379.8588|
|200-day moving average||$313.1212|
|Wall St. target price||$427.4|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$5.286|
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Valuing IDEXX Laboratories stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of IDEXX Laboratories's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
IDEXX Laboratories's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 67x. In other words, IDEXX Laboratories shares trade at around 67x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
However, IDEXX Laboratories's P/E ratio is best considered in relation to those of others within the diagnostics & research industry or those of similar companies.
IDEXX Laboratories's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 5.2. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into IDEXX Laboratories's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
However, it's sensible to consider IDEXX Laboratories's PEG ratio in relation to those of similar companies.
IDEXX Laboratories's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $698.2 million (£0.0 million).
The EBITDA is a measure of a IDEXX Laboratories's overall financial performance and is widely used to measure a its profitability.
To put IDEXX Laboratories's EBITDA into context you can compare it against that of similar companies.
|Revenue TTM||$2.5 billion|
|Operating margin TTM||24.5%|
|Gross profit TTM||$1.4 billion|
|Return on assets TTM||20.57%|
|Return on equity TTM||206.87%|
|Market capitalisation||$30.7 billion|
TTM: trailing 12 months
There are currently 1.2 million IDEXX Laboratories shares held short by investors – that's known as IDEXX Laboratories's "short interest". This figure is 1.6% up from 1.2 million last month.
There are a few different ways that this level of interest in shorting IDEXX Laboratories shares can be evaluated.
IDEXX Laboratories's "short interest ratio" (SIR) is the quantity of IDEXX Laboratories shares currently shorted divided by the average quantity of IDEXX Laboratories shares traded daily (recently around 476295.71984436). IDEXX Laboratories's SIR currently stands at 2.57. In other words for every 100,000 IDEXX Laboratories shares traded daily on the market, roughly 2570 shares are currently held short.
To gain some more context, you can compare IDEXX Laboratories's short interest ratio against those of similar companies.
However IDEXX Laboratories's short interest can also be evaluated against the total number of IDEXX Laboratories shares, or, against the total number of tradable IDEXX Laboratories shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case IDEXX Laboratories's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 IDEXX Laboratories shares in existence, roughly 10 shares are currently held short) or 0.0164% of the tradable shares (for every 100,000 tradable IDEXX Laboratories shares, roughly 16 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against IDEXX Laboratories.
Find out more about how you can short IDEXX Laboratories stock.
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like IDEXX Laboratories.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 30.77
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and IDEXX Laboratories's overall score of 30.77 (as at 08/01/2020) is nothing to write home about – landing it in it in the 54th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like IDEXX Laboratories is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
To gain some more context, you can compare IDEXX Laboratories's total ESG risk score against those of similar companies.
Environmental score: 9.93/100
IDEXX Laboratories's environmental score of 9.93 puts it squarely in the 6th percentile of companies rated in the same sector. This could suggest that IDEXX Laboratories is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 14.44/100
IDEXX Laboratories's social score of 14.44 puts it squarely in the 6th percentile of companies rated in the same sector. This could suggest that IDEXX Laboratories is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 13.89/100
IDEXX Laboratories's governance score puts it squarely in the 6th percentile of companies rated in the same sector. That could suggest that IDEXX Laboratories is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
|Total ESG score||30.77|
|Total ESG percentile||53.74|
|Environmental score percentile||6|
|Social score percentile||6|
|Governance score percentile||6|
We're not expecting IDEXX Laboratories to pay a dividend over the next 12 months. However, you can browse other dividend-paying shares in our guide.
You may also wish to consider:
IDEXX Laboratories's shares were split on a 2:1 basis on 16 June 2015. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your IDEXX Laboratories shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for IDEXX Laboratories shares which in turn could have impacted IDEXX Laboratories's share price.
Over the last 12 months, IDEXX Laboratories's shares have ranged in value from as little as $168.65 up to $407.86. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while IDEXX Laboratories's is 0.8049. This would suggest that IDEXX Laboratories's shares are less volatile than average (for this exchange).
To put IDEXX Laboratories's beta into context you can compare it against those of similar companies.
IDEXX Laboratories, Inc., together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers that are used in the human point-of-care medical diagnostics market. It markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.